Shengke Pharmaceuticals is seeking collaboration opportunities for our proprietary oncology assets targeting kinase inhibitors and other targets. We are also seeking collaborations with academic investigators and clinical sites interested in exploring program potential and novel approaches to boosting targeted therapy.

Currently, worldwide rights to all pipeline programs are owned by Shengke Pharmaceuticals.

As part of our strategy, we also focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and other diseases and then seek to further develop these drug candidates for commercial use.

Collaboration Inquiry. Please contact [email protected]